perampanel + perampanel + perampanel + Placebo
Phase 3Completed 1 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Refractory Partial Seizures
Conditions
Refractory Partial Seizures
Trial Timeline
Aug 1, 2008 → Jan 1, 2010
NCT ID
NCT00700310About perampanel + perampanel + perampanel + Placebo
perampanel + perampanel + perampanel + Placebo is a phase 3 stage product being developed by Eisai for Refractory Partial Seizures. The current trial status is completed. This product is registered under clinical trial identifier NCT00700310. Target conditions include Refractory Partial Seizures.
What happened to similar drugs?
3 of 20 similar drugs in Refractory Partial Seizures were approved
Approved (3) Terminated (2) Active (15)
🔄SHR2554; Chidamide analog tablets + SHR2554 analog tablets; ChidamideJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00700310 | Phase 3 | Completed |
Competing Products
20 competing products in Refractory Partial Seizures